title: Monocyte chemoattractant protein-1 in patients with peripheral arterial disease.
abstract: BACKGROUND
  Chemokine-driven migration of inflammatory cells has been implicated in the pathogenesis of atherosclerotic conditions including peripheral arterial disease (PAD). Monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with coronary artery disease and in hypertensive patients. This study therefore investigated MCP-1 in patients with PAD.
  
  
  METHODS
  Serum MCP-1 was determined by enzyme-linked immunosorbent assay in 36 healthy, control subjects and in 19 patients with PAD. Statistical analysis utilised the Mann-Whitney test and Spearman correlation (p < 0.05).
  
  
  RESULTS
  MCP-1 (pg/ml) was increased in patients compared with in controls (mean+/-standard error of the mean: PAD group, 748+/-60; control group, 459+/-27; p=0.0001). MCP-1 levels tended to decrease with progressing disease. From atherosclerosis risk factors, diabetes inclined to increase MCP-1 levels; hypertension had no effect. Serum MCP-1 correlated with cholesterol, triglycerides, low-density lipoprotein but not high-density lipoprotein.
  
  
  CONCLUSIONS
  Elevation of MCP-1 in the circulation of PAD patients shown in the present pilot study implicates this CC chemokine ligand 2 in inflammatory processes contributing to PAD clinical symptomatology. Further investigations are necessary to evaluate whether MCP-1 can be used as a potential marker of peripheral arterial disease follow-up and/or prognosis.
authors.affiliation: Department of Immunology, Palacky University and Faculty Hospital, Olomouc, Czech Republic.
authors.forename: Jana
authors.initials: J
authors.lastname: Petrkova
authors.forename: Jaroslava
authors.initials: J
authors.lastname: Szotkowska
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Hermanova
authors.forename: Jan
authors.initials: J
authors.lastname: Lukl
authors.forename: Martin
authors.initials: M
authors.lastname: Petrek
mesh_terms: D000368:Aged; D001158:Arteries; D001161:Arteriosclerosis / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D018932:Chemokine CCL2 / Q000097:blood*; D048909:Diabetes Complications; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D007118:Immunoassay; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D016491:Peripheral Vascular Diseases / Q000097:blood* / Q000150:complications; D010865:Pilot Projects; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D015415:Biomarkers; D018932:Chemokine CCL2; D008055:Lipids